Treatment of Progressive Multifocal Leukoencephalopathy with Pembrolizumab

N Engl J Med. 2019 Apr 25;380(17):1676-1677. doi: 10.1056/NEJMc1817193. Epub 2019 Apr 10.

Authors

Sebastian Rauer¹, Reinhard Marks¹, Horst Urbach¹, Klaus Warnatz¹, Avindra Nath², Steve Holland², Cornelius Weiller³, Bodo Grimbacher³

Affiliations

¹ Albert Ludwigs University, Freiburg, Germany sebastian.rauer@uniklinik-freiburg.de.
² National Institutes of Health, Bethesda, MD.
³ Albert Ludwigs University, Freiburg, Germany.

PMID: 30969507
DOI: 10.1056/NEJMc1817193

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Brain / diagnostic imaging
CD8-Positive T-Lymphocytes / physiology
Cerebrospinal Fluid / virology
Humans
Immunologic Factors / therapeutic use*
JC Virus / isolation & purification*
Leukoencephalopathy, Progressive Multifocal / diagnostic imaging
Leukoencephalopathy, Progressive Multifocal / drug therapy*
Magnetic Resonance Imaging
Male
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Programmed Cell Death 1 Receptor / metabolism
Viral Load
White Matter / diagnostic imaging
White Matter / pathology

Substances

Antibodies, Monoclonal, Humanized
Immunologic Factors
PDCD1 protein, human
Programmed Cell Death 1 Receptor
pembrolizumab